$59.40−2.21 (−3.59%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Vaxcyte (PCVX) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld. Worth your attention in FY25: Share count (+162.1%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▼65.2%
−766.6
FY21→FY25CAGR —
Free cash flow ($M)▼40.9%
−669.3
FY21→FY25CAGR —
Diluted EPS▼48.2%
−5.63
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+162.1%
51.9mn → 136.1mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$13.7M
−38.9% YoY in FY25.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
Margin trend · direction beats level
This filer reports no gross profit or operating income line, so those margins are not drawn.
The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Research & development | 1,093.0 | 794.3 | 476.6 | 332.3 | 169.5 | 78.4 | ▲66.6% | +78.4% |
Selling, general & admin | 138.2 | 129.4 | 92.9 | 60.7 | 39.8 | 25.3 | ▲39.3% | +50.4% |
Total operating expenses | 1,231.2 | 923.7 | 569.5 | 468.0 | 232.3 | 103.7 | ▲62.2% | +72.8% |
Operating incomefeeds ROC rank | −1,231.2 | −923.7 | −569.5 | −468.0 | −232.3 | −103.7 | ▼62.2% | — |
Other income, net | 84.4 | 157.0 | 105.6 | 65.8 | 8.8 | 3.6 | — | — |
Pretax income | −1,146.8 | −766.6 | −463.9 | −402.3 | −223.5 | −100.1 | ▼65.2% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −1,148.5 | −766.6 | −463.9 | −402.3 | −223.5 | −100.1 | ▼65.2% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −8.07 | −5.63 | −3.80 | −4.14 | −3.44 | −1.93 | ▼48.2% | — |
Diluted shares (mn) | 148.91 | 136.09 | 122.00 | 97.16 | 64.88 | 51.92 | ▲11.6% | +27.2% |
| Margins | ||||||||
† TTM = trailing four quarters through 2026-09-30.
3 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-24 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

